liquid biopsy

Viewing posts tagged liquid biopsy

Precision Medicine Beyond the Genome

Today, doctors can tailor a drug therapy to your unique genetic profile, giving you the full benefits of a drug while reducing unwanted side effects — all in harmony with the blueprints of your biology.

Now, through a new $30,000 grant from the J.R. & Inez Jay Fund, researchers at the University of Kansas and Children’s Mercy Hospital in Kansas City are investigating how to tailor drug therapies using exosomes — nanoscale sacs full of biomarkers like lipids, proteins and nucleic acids found in bodily fluids — that can be used to achieve a noninvasive “liquid biopsy.”

“Beyond genetics, there are layers of complexities during development from childhood to adolescence to adulthood.”

–Michael Wang, University of Kansas

The new exosome-based technology could be especially useful in developing personalized medical treatments for children and teens, Wang said.

For the full story visit the University of Kansas website here.

Visit the University of Kansas

Liquid Biopsy Boom

If liquid biopsies can prove effective as a diagnostic tool in the pre- and post-cancer settings, some in the industry predict the market’s value could balloon to anywhere from $20 billion to over $100 billion, according to a recent article BioPharma Dive.

Forentis finds this interesting, as much of our focus is on funding the research that can bring these types of diagnostics to market. Advancing precision medicine by applying new technologies like liquid biopsies is in our DNA. Liquid biopsies and clinical trial enrichment are critical to developing the precision treatments and companion diagnostics that will make precision medicine a reality.

“Another use of liquid biopsies is in clinical trials. As targeted therapies proliferate, pharma companies need to cast a wide net in order to enroll patients who match the specific criteria of drug studies. Using liquid biopsies to screen patients could greatly accelerate enrollment as well as lowering costs.”

BioPharma Dive

What is exciting to us is that while the industry is focused on circulating tumor cell biomarkers, we are going deeper into the human biology. If you are interested in finding out more about how we are accessing multi-omic biomarkers – give us a call!

Liquid Biopsy Market Set to Explode

The Global Liquid Biopsy Market has been assessed as a swiftly growing market and it is expected that the market will reach high growth figures and boom in the coming future, according to a report from Market Research Future.

According to the report, there is enormous demand for liquid biopsy in the research laboratories of pharmaceutical and biotechnology companies as drug development is one of the major applications of the technology.
There has been a tremendous growth in the prevalence of cancer disease and the global population getting diagnosed with cancer. The firm estimates that the Liquid Biopsy market is expected to grow at a CAGR of 21.6% from 2016 to 2022.